Cleveland Clinic 2004 Medical Innovation Summit In Brief
This article was originally published in The Gray Sheet
Executive Summary
Market leader or fast follower?: Guidant's ability to bypass FDA panel review and be first to the U.S. market in August with the Rx Acculink carotid stent suggests an advantage to being a "fast follower," rather than the originator of a brand-new therapy, according to vascular interventionalist Jay Yadav, MD, Cleveland Clinic Foundation. J&J/Cordis' Precise carotid stent withstood panel review and had been widely projected as the first-comer, but still awaits final FDA sign-off. "There is some consternation in the medical device community that it may be more efficient - you may save tens of millions of dollars - by waiting a couple of months and being a fast follower," Yadav claims. "Do we really want an [FDA] environment where true innovation is discouraged for business reasons?"...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.